Wire · operational-macro
Shionogi strikes $2B deal for IntraBio hot off FDA label expansion
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
Shionogi acquired Austin-based biotech IntraBio for $2 billion, gaining its rare disease drug portfolio including the newly label-expanded Aqneursa. This deal strengthens Shionogi's focus on rare diseases, complementing its prior acquisition of Radicava and supporting multiple clinical programs.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 5 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
Rare disease founders in the US now face bigger competitors acquiring proven assets and pipelines rapidly. You need to find partners or differentiate fast before consolidation shifts market access and funding toward established players like Shionogi.
◆ Coverage
5 sources · first reported 5 Oct 2026 · latest 6 Oct 2026
◆ Related on Wire
◆ Topics